Neil Woodford's decision to charge a performance fee but no AMC on his new Patient Capital trust has left analysts asking whether the move will accelerate price pressures in the closed-ended space.
Woodford has set a performance fee of 15% on any excess returns above his Patient Capital trust's 10% annual return target. The board of the trust has also reassured investors its performance fee will have a "high watermark", to prevent management claiming fees on returns that are simply making up losses from previous years. Ongoing annual expenses are not expected to exceed 0.35%. However, the decision to charge a performance fee runs counter to moves by many in the sector to scrap this method of charging in the last few years. A total of 27 investment trusts have removed performance...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes